Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
79 hedge funds and large institutions have $17.6M invested in Acorda Therapeutics in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 27 reducing their positions, and 45 closing their positions.
25% less funds holding
Funds holding: 106 → 79 (-27)
48% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 27
56% less capital invested
Capital invested by funds: $39.9M → $17.6M (-$22.3M)
60% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 45
96% less call options, than puts
Call options by funds: $101K | Put options by funds: $2.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$515K |
| 2 |
Millennium Management
New York
|
+$400K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$249K |
| 4 |
Jane Street
New York
|
+$229K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.02M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.42M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.28M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$777K |
ACOR Hedge Fund Activity: Q2 2020 in Review
79 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2020, worth a combined $17.6M — down 56% from $39.9M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of ACOR and 18 opened new positions — a net loss of 27 holders — while 27 trimmed existing stakes and 14 added.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $515K. The largest seller was BlackRock, cutting an estimated $5.44M.
- 79 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2020, down from 106 in Q1 2020.
- Funds reported $17.6M of Acorda Therapeutics stock for Q2 2020, down 56% quarter-over-quarter.
- 18 funds opened new Acorda Therapeutics positions in Q2 2020 and 45 closed out, a net change of -27 holders.
- The largest Acorda Therapeutics buyer in Q2 2020 was Arrowstreet Capital, an estimated $515K added.
- The largest Acorda Therapeutics seller in Q2 2020 was BlackRock, an estimated $5.44M sold.
Based on aggregated 13F filings for Q2 2020.